Tempus AI CEO Claims AI Blood Tests Detect Cancer Recurrence Months Earlier Than Scans
Rapid Read

Tempus AI CEO Claims AI Blood Tests Detect Cancer Recurrence Months Earlier Than Scans

What's Happening? Eric Lefkofsky, founder and CEO of Tempus AI, asserts that artificial intelligence trained on multimodal cancer data can identify cancer recurrence in patients from a blood draw six to twelve months before traditional scans. This claim is linked to Tempus's impending acquisition of
AI Generated
This may include content generated using AI tools. Glance teams are making active and commercially reasonable efforts to moderate all AI generated content. Glance moderation processes are improving however our processes are carried out on a best-effort basis and may not be exhaustive in nature. Glance encourage our users to consume the content judiciously and rely on their own research for accuracy of facts. Glance maintains that all AI generated content here is for entertainment purposes only.